Milbemycin Oxime
| 매개변수 | 사양 |
|---|---|
| 제품명 | Milbemycin Oxime |
| CAS 번호 | 129496-10-2 |
| 분자식 | C63H88N2O14 (mixture of A3 and A4 oximes) |
| 분자량 | 1097.4 g/mol (A4), 1083.4 g/mol (A3) |
| 외관 | Off-white to pale yellow crystalline powder |
| 분석법 (HPLC) | ≥ 95.0% (sum of milbemycin A3 and A4 oximes) |
| 용해도 | Soluble in methanol, ethanol, acetone; practically insoluble in water |
| 패키지 | 1 kg, 5 kg, 25 kg fiber drums |
도움이 필요하신가요? 저희 팀에 문의해 주세요
동의어: Milbemycin oxime, Milbemycin 5-oxime, A3/A4 oxime, Interceptor, Sentinel, 129496-10-2
Milbemycin oxime is a semi-synthetic macrocyclic lactone derived from the natural fermentation products of Streptomyces hygroscopicus var. aureolacrimosus. Structurally, it is a mixture of two homologous oxime derivatives, milbemycin A3 oxime and milbemycin A4 oxime, typically in a ratio of about 20:80. This molecule belongs to the milbemycin family, which shares mechanistic similarities with the avermectins but lacks the disaccharide substituent at C-13. The oxime modification at C-5 significantly enhances antiparasitic potency and extends the spectrum of activity compared to the parent milbemycins. First developed by Sankyo (now part of Mitsubishi Tanabe Pharma) and later marketed by Novartis, milbemycin oxime has become a mainstay in veterinary medicine for the prevention and treatment of a broad range of endo- and ectoparasites in dogs and cats.
In terms of chemical behavior, milbemycin oxime is a lipophilic compound that acts on glutamate-gated chloride channels in invertebrates, leading to hyperpolarization of nerve and muscle cells, paralysis, and eventual death of the parasite. Its selectivity for invertebrate channels over mammalian ones underpins its wide margin of safety. The A3 and A4 components differ by a single methylene group, which slightly affects their pharmacokinetic profiles but both contribute to the overall efficacy. The oxime group also improves stability and allows for formulation into chewable tablets, topical spot-ons, and injectables.
Commercially, milbemycin oxime is standardized to a minimum of 95% total oximes (A3 + A4) by HPLC, with individual component ratios controlled to ensure consistent biological performance. It is primarily used as an active pharmaceutical ingredient (API) in veterinary parasiticides, often in combination with other agents such as praziquantel or lufenuron to broaden the spectrum. The compound is also investigated for use in human medicine, though its main market remains animal health. Its effectiveness against heartworm (Dirofilaria immitis), roundworms, hookworms, and whipworms has made it a key component in monthly preventive products.
| Test Item | 사양 |
|---|---|
| 식별 | IR spectrum conforms to reference standard |
| 건조 손실 | ≤ 2.0% |
| 소각 잔류물 | ≤ 0.2% |
| 중금속 | ≤ 20 ppm |
| Organic Impurities | Any individual impurity ≤ 1.0%; total impurities ≤ 3.0% |
| 잔류 용매 | Meets ICH Q3C requirements |
| Microbial Limits | Total aerobic count ≤ 1000 CFU/g; yeast & mold ≤ 100 CFU/g; absence of E. coli and Salmonella |
Our standard MOQ is 1 kg. For larger quantities, we offer competitive pricing and can accommodate custom packaging.
For stock items, delivery is 3-5 business days after order confirmation. We ship from our warehouse and provide tracking information promptly.
Yes, we provide a COA for each batch. Samples are available upon request; please contact our sales team for sample arrangements. Documentation such as MSDS and TDS can be provided within 1-2 days.
send us your specification for a quotation.
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese